Open Access. Powered by Scholars. Published by Universities.®

Medical Neurobiology Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 2 of 2

Full-Text Articles in Medical Neurobiology

Neuromotor And Cognitive Development In Children With Cerebral Palsy In Relation To Neural Plasticity, Vaniecea Pollard May 2001

Neuromotor And Cognitive Development In Children With Cerebral Palsy In Relation To Neural Plasticity, Vaniecea Pollard

McCabe Thesis Collection

Infants with neurological disabilities, such as cerebral palsy (CP) and Down syndrome (DS), show severe delays in motor and cognitive development relative to chronological age. Involvement of neural plasticity as a treatment of such neurological disorders is increasingly being seen. Previous studies have found that interventions involving sensory linked motor performance have been critical in facilitating motor improvement. The purpose of this study was to compare self-initiated mobility in children with CP and DS. Three infants, ages 8, 9, and 22 months, with diagnoses of no CP, DS, and CP respectively, participated in the study. The infants were videotaped in …


Role Of Ampa And Glur5 Kainate Receptors In The Development And Expression Of Amygdala Kindling In The Mouse, Michael A. Rogawski, Philip S. Kurzman, Shun-Ichi Yamaguchi, He Li Dec 2000

Role Of Ampa And Glur5 Kainate Receptors In The Development And Expression Of Amygdala Kindling In The Mouse, Michael A. Rogawski, Philip S. Kurzman, Shun-Ichi Yamaguchi, He Li

Michael A. Rogawski

The role of AMPA and GluR5-containing kainate receptors in the development and expression of amygdala kindling was examined using the selective 2,3-benzodiazepine AMPA receptor antagonist GYKI 52466 [(1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2, 3-benzodiazepine] and the decahydroisoquinoline mixed AMPA receptor and GluR5 kainate receptor antagonist LY293558 {(3S,4aR,6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline- 3-carboxy lic acid)}. Administration of GYKI 52466 (5-40 mg/kg, intraperitoneally) and LY293558 (10-40 mg/kg, intraperitoneally) prior to daily kindling stimulation in mice produced a dose-dependent suppression of the rate of development of behavioral kindled seizure activity and reduced the duration of the stimulation-induced electrographic afterdischarge. In drug-free stimulation sessions after the initial drug-treatment sessions, there was an …